Research & Development

share on google plus
Text size
view with small font size
view with medium font size
view with large font size

Pipeline

Last update: Jan.31st, 2017 PDF file:New window opensKyowa Hakko Kirin R&D Pipeline(95KB)

Since Oct 21th, 2016

Search

Modalities:
Therapeutic Area:

Code Name
Generic name

Therapeutic
Area

Indication

Phase
123F/A

Region

AMG531 Romiplostim

Idiopathic (Immune) Thrombocytopenic Purpura

F/A

Filed in TH

Therapeutic Area :
Region : Filed in TH
Formulation : Injection
Mechanism of Action : Thrombopoietin Receptor Agonist
In-House or Licensed : Kirin-Amgen

X-linked
Hypophosphatemia (XLH)

F/A

EU

Therapeutic Area :
Region : EU
Formulation : Injection
Mechanism of Action : Anti-FGF23 Fully Human Antibody
In-House or Licensed : In-House
Project Type : New Molecular Entity
Remarks : Human Antibody-Producing Technology
Jointly Developed with Ultragenyx in US and EU

KRN321 Darbepoetin Alfa

Renal Anemia (on Dialysis)

F/A

NDA in preparation in CN

Therapeutic Area :
Region : NDA in preparation in CN
Formulation : Injection
Mechanism of Action : Long-Acting Erythropoiesis Stimulating Agent
In-House or Licensed : Kirin-Amgen

KRN321 Darbepoetin Alfa

Renal Anemia

F/A

Filed in ID

Therapeutic Area :
Region : Filed in ID
Formulation : Injection
Mechanism of Action : Long-Acting Erythropoiesis Stimulating Agent
In-House or Licensed : Kirin-Amgen

KRN321 Darbepoetin Alfa

Myelodysplastic Syndromes

F/A

Filed in HK, SG, MY

Therapeutic Area :
Region : Filed in HK, SG, MY
Formulation : Injection
Mechanism of Action : Long-Acting Erythropoiesis Stimulating Agent
In-House or Licensed : Kirin-Amgen

Z-206 Mesalazine

Ulcerative Colitis

F/A

Filed in JP

Therapeutic Area :
Region : Filed in JP
Formulation : Oral
Mechanism of Action : pH Dependent Controlled Release Tablet
In-House or Licensed : Zeria Pharma
Remarks : Jointly Developed with Zeria Pharma
(Additional Dosage and Administration)

Cinacalcet Hydrochloride

Secondary
Hyperparathyroidism

F/A

Filed in BN

Therapeutic Area :
Region : Filed in BN
Formulation : Oral
Mechanism of Action : Calcium Receptor Agonist
In-House or Licensed : NPS

Granisetron

Chemotheraphy induced
Nausea and Vomiting

F/A

Filed in MY

Therapeutic Area :
Region : Filed in MY
Formulation : Patch
Mechanism of Action : 5-HT3 Serotonin Recepter Antagonist
In-House or Licensed : Solasia Pharma

AMG531 Romiplostim

Idiopathic (Immune) Thrombocytopenic Purpura

3

CN

Therapeutic Area :
Region : CN
Formulation : Injection
Mechanism of Action : Thrombopoietin Receptor Agonist
In-House or Licensed : Kirin-Amgen

AMG531 Romiplostim

Aplastic Anemia

3

JP and KR

Therapeutic Area :
Region : JP and KR
Formulation : Injection
Mechanism of Action : Thrombopoietin Receptor Agonist
In-House or Licensed : Kirin-Amgen

ARQ 197 Tivantinib

Hepatocellular Cancer

3

JP

Therapeutic Area :
Region : JP
Formulation : Oral
Mechanism of Action : c-Met Inhibitor
In-House or Licensed : ArQule
Project Type : New Molecular Entity

KHK4563 Benralizumab

Asthma

3

JP and KR

Therapeutic Area :
Region : JP and KR
Formulation : Injection
Mechanism of Action : Anti-IL-5 Receptor Humanized Antibody
In-House or Licensed : In-House
Project Type : New Molecular Entity
Remarks : Jointly Developed with AstraZeneca/MedImmune in JP and KR
POTELLIGENT®

KHK4563 Benralizumab

Chronic Obstructive Pulmonary Disease (COPD)

3

JP

Therapeutic Area :
Region : JP
Formulation : Injection
Mechanism of Action : Anti-IL-5 Receptor Humanized Antibody
In-House or Licensed : In-House
Project Type : New Molecular Entity
Remarks : Jointly Developed with AstraZeneca/MedImmune in JP and KR
POTELLIGENT®

KHK4827 Brodalumab

Psoriasis

3

KR

Therapeutic Area :
Region : KR
Formulation : Injection
Mechanism of Action : Anti-IL-17 Receptor A Fully Human Antibody
In-House or Licensed : Kirin-Amgen

Secondary
Hyperparathyroidism

3

JP

Therapeutic Area :
Region : JP
Formulation : Oral
Mechanism of Action : Calcium Receptor Agonist
In-House or Licensed : Mitsubishi Tanabe Pharma
Project Type : New Molecular Entity

X-linked Hypophosphatemia (XLH) in adult patients

3

US, CA, EU, JP and KR

Therapeutic Area :
Region : US, CA, EU, JP and KR
Formulation : Injection
Mechanism of Action : Anti-FGF23 Fully Human Antibody
In-House or Licensed : In-House
Project Type : New Molecular Entity
Remarks : Human Antibody-Producing Technology
Jointly Developed with Ultragenyx in US and EU

X-linked Hypophosphatemia (XLH) in pediatric patients

3

US, CA, EU, AU, JP, KR

Therapeutic Area :
Region : US, CA, EU, AU, JP, KR
Formulation : Injection
Mechanism of Action : Anti-FGF23 Fully Human Antibody
In-House or Licensed : In-House
Project Type : New Molecular Entity
Remarks : Human Antibody-Producing Technology
Jointly Developed with Ultragenyx in US and EU

KW-0761 Mogamulizumab

Cutaneous T-cell
Lymphoma

3

US, EU, JP and others

Therapeutic Area :
Region : US, EU, JP and others
Formulation : Injection
Mechanism of Action : Anti-CCR4 Humanized Antibody
In-House or Licensed : In-House
Remarks : POTELLIGENT®

KW-6002 Istradefylline

Parkinson's Disease

3

US, CA, EU and others

Therapeutic Area :
Region : US, CA, EU and others
Formulation : Oral
Mechanism of Action : Adenosine A2A Receptor Antagonist
In-House or Licensed : In-House

Organ Transplant Rejection

2

US

Therapeutic Area :
Region : US
Formulation : Injection
Mechanism of Action : Anti-CD40 Fully Human Antibody
In-House or Licensed : In-House
Project Type : New Molecular Entity
Remarks : Jointly Developed with Astellas
Human Antibody-Producing Mouse

Ulcerative Colitis

2

US, EU, and others

Therapeutic Area :
Region : US, EU, and others
Formulation : Injection
Mechanism of Action : Anti-OX40 Fully Human Antibody
In-House or Licensed : In-House
Project Type : New Molecular Entity
Remarks : POTELLIGENT®
Human Antibody-Producing Mouse

KHK4563 Benralizumab

Eosinophilic Chronic Rhinosinusitis (ECRS)

2

JP

Therapeutic Area :
Region : JP
Formulation : Injection
Mechanism of Action : Anti-IL-5 Receptor Humanized Antibody
In-House or Licensed : In-House
Project Type : New Molecular Entity
Remarks : POTELLIGENT®

Tumor Induced Osteomalacia(TIO) / Epidermal Nevus Syndrome (ENS)

2

US

Therapeutic Area :
Region : US
Formulation : Injection
Mechanism of Action : Anti-FGF23 Fully Human Antibody
In-House or Licensed : In-House
Project Type : New Molecular Entity
Remarks : Human Antibody-Producing Technology
Jointly Developed with Ultragenyx in US and EU

Tumor Induced Osteomalacia(TIO) / Epidermal Nevus Syndrome (ENS)

2

JP and KR

Therapeutic Area :
Region : JP and KR
Formulation : Injection
Mechanism of Action : Anti-FGF23 Fully Human Antibody
In-House or Licensed : In-House
Project Type : New Molecular Entity
Remarks : Human Antibody-Producing Technology

KW-0761 Mogamulizumab

Adult T-cell
Leukemia/Lymphoma

2

US, EU and others

Therapeutic Area :
Region : US, EU and others
Formulation : Injection
Mechanism of Action : Anti-CCR4 Humanized Antibody
In-House or Licensed : In-House
Remarks : POTELLIGENT®

Parkinson's Disease

2

JP

Therapeutic Area :
Region : JP
Formulation : Oral
Mechanism of Action : Adenosine A2A Receptor Antagonist
In-House or Licensed : In-House
Project Type : New Molecular Entity

RTA 402 Bardoxolone Methyl

CKD in Patients with Type 2 Diabetes

2

JP

Therapeutic Area :
Region : JP
Formulation : Oral
Mechanism of Action : Antioxidant Inflammation Modulator
In-House or Licensed : Reata
Project Type : New Molecular Entity

Organ Transplant Rejection

1

JP

Therapeutic Area :
Region : JP
Formulation : Injection
Mechanism of Action : Anti-CD40 Fully Human Antibody
In-House or Licensed : In-House
Project Type : New Molecular Entity
Remarks : Jointly Developed with Astellas
Human Antibody-Producing Mouse

KHK2375 Entinostat

Breast Cancer

1

JP

Therapeutic Area :
Region : JP
Formulation : Oral
Mechanism of Action : HDAC Inhibitor
In-House or Licensed : Syndax
Project Type : New Molecular Entity

Solid Tumor

1

US

Therapeutic Area :
Region : US
Formulation : Oral
Mechanism of Action : IDO 1 Inhibitor
In-House or Licensed : In-House
Project Type : New Molecular Entity
Remarks : Combination with KW-0761

Cancer

1

UK

Therapeutic Area :
Region : UK
Formulation : Injection
Mechanism of Action : Anti-CD123 Fully Human Antibody
In-House or Licensed : In-House
Project Type : New Molecular Entity
Remarks : POTELLIGENT®
Human Antibody-Producing Mouse

Ulcerative Colitis

1

JP

Therapeutic Area :
Region : JP
Formulation : Injection
Mechanism of Action : Anti-OX40 Fully Human Antibody
In-House or Licensed : In-House
Project Type : New Molecular Entity
Remarks : POTELLIGENT®
Human Antibody-Producing Mouse

Alzheimer's Disease

1

JP

Therapeutic Area :
Region : JP
Formulation : Injection
Mechanism of Action : Anti-Amyloid Beta Peptide Antibody
In-House or Licensed : Immunas Pharma
Project Type : New Molecular Entity

Alzheimer's Disease

1

EU

Therapeutic Area :
Region : EU
Formulation : Injection
Mechanism of Action : Anti-Amyloid Beta Peptide Antibody
In-House or Licensed : Immunas Pharma
Project Type : New Molecular Entity

KW-0761 Mogamulizumab

Solid Tumor

1

US

Therapeutic Area :
Region : US
Formulation : Injection
Mechanism of Action : Anti-CCR4 Humanized Antibody
In-House or Licensed : In-House
Remarks : Combination with Durvalumab / Tremelimumab
(Jointly Developed with AstraZeneca)
POTELLIGENT®

KW-0761 Mogamulizumab

Solid Tumor

1

US

Therapeutic Area :
Region : US
Formulation : Injection
Mechanism of Action : Anti-CCR4 Humanized Antibody
In-House or Licensed : In-House
Remarks : Combination with Docetaxel
POTELLIGENT®

KW-0761 Mogamulizumab

Solid Tumor

1

US

Therapeutic Area :
Region : US
Formulation : Injection
Mechanism of Action : Anti-CCR4 Humanized Antibody
In-House or Licensed : In-House
Remarks : Combination with PF-05082566
(Jointly Developed with Pfizer)
POTELLIGENT®

KW-0761 Mogamulizumab

Solid Tumor

1

US

Therapeutic Area :
Region : US
Formulation : Injection
Mechanism of Action : Anti-CCR4 Humanized Antibody
In-House or Licensed : In-House
Remarks : Combination with Nivolumab
(Jointly Developed with Bristol-Myers Squibb)
POTELLIGENT®

KW-0761 Mogamulizumab

Solid Tumor

1

JP

Therapeutic Area :
Region : JP
Formulation : Injection
Mechanism of Action : Anti-CCR4 Humanized Antibody
In-House or Licensed : In-House
Remarks : Combination with Nivolumab
(Jointly Developed with Ono Pharmaceutical)
POTELLIGENT®

KW-3357 Antithrombin Gamma

Disseminated
Intravascular Coagulation,
Congenital Antithrombin
Deficiency

1

EU

Therapeutic Area :
Region : EU
Formulation : Injection
Mechanism of Action : Recombinant Human Antithrombin
In-House or Licensed : In-House

New / Advanced

Code Name
Generic name

Therapeutic Area

Indication

Phase
123F/A

Region

X-linked
Hypophosphatemia (XLH)

F/A

EU

Therapeutic Area :
Region : EU
Formulation : Injection
Mechanism of Action : Anti-FGF23 Fully Human Antibody
In-House or Licensed : In-House
Project Type : New Molecular Entity
Remarks : Human Antibody-Producing Technology
Jointly Developed with Ultragenyx in US and EU

KHK4827 Brodalumab

Psoriasis

3

KR

Therapeutic Area :
Region : KR
Formulation : Injection
Mechanism of Action : Anti-IL-17 Receptor A Fully Human Antibody
In-House or Licensed : Kirin-Amgen

X-linked Hypophosphatemia (XLH) in pediatric patients

3

US, CA, EU, AU, JP, KR

Therapeutic Area :
Region : US, CA, EU, AU, JP, KR
Formulation : Injection
Mechanism of Action : Anti-FGF23 Fully Human Antibody
In-House or Licensed : In-House
Project Type : New Molecular Entity
Remarks : Human Antibody-Producing Technology
Jointly Developed with Ultragenyx in US and EU

Parkinson's Disease

2

JP

Therapeutic Area :
Region : JP
Formulation : Oral
Mechanism of Action : Adenosine A2A Receptor Antagonist
In-House or Licensed : In-House
Project Type : New Molecular Entity

Ulcerative Colitis

1

JP

Therapeutic Area :
Region : JP
Formulation : Injection
Mechanism of Action : Anti-OX40 Fully Human Antibody
In-House or Licensed : In-House
Project Type : New Molecular Entity
Remarks : POTELLIGENT®
Human Antibody-Producing Mouse

Removed

Code Name
Generic name

Therapeutic Area

Indication

Phase
123F/A

Region

KRN951Tivozanib

Cancer

1

JP

Therapeutic Area :
Region : JP
Formulation : Oral
Mechanism of Action : VEGF Receptor Inhibitor
In-House or Licensed : In-House
Project Type : New Molecular Entity
Remarks : Being Developed overseas by AVEO as AV-951

To Page Top